MONTREAL, June 8 /CNW/ - ConjuChem Biotechnologies, Inc. (TSX:CJB), today
announced that it presented two posters at the 69th Scientific Sessions of the
2009 American Diabetes Association meeting held in New Orleans, LA on June
5-9, 2009. The first poster detailed previously disclosed results of two
randomized, double-blind, placebo controlled phase II trials of
PC-DAC(TM):Exendin-4, demonstrating that this long-lasting GLP-1 receptor
agonist can significantly and safely reduce HbA1c and body weight. The second
poster describes PC-Insulin, a novel insulin-albumin conjugate demonstrating a
prolonged duration of activity in preclinical pharmacodynamic studies.
"The presentations highlight the unique and highly competitive aspects of
our two diabetes products, and showcase the value of our proprietary approach
to extending the therapeutic window of short-lived therapeutic peptides," said
Dr. Thomas Ulich, Executive Vice President, Research and Development at
ConjuChem. "In the case of PC-DAC(TM):Exendin-4, we achieved statistically
significant glycemic control and weight loss in Type 2 diabetes patients with
a small volume liquid formulation injected through a fine 31 gauge needle. In
the case of PC-Insulin, preclinical studies promise a more peakless,
longer-lasting basal insulin that we plan to advance into human clinical
The first poster is entitled: "PC-DAC(TM):Exendin-4 (CJC-1134-PC)
Significantly Reduces HbA1c and Body Weight as an Adjunct Therapy to
Metformin: Two Randomized, Double-Blind, Placebo-Controlled, 12 Week, Phase II
Studies in Patients with Type 2 Diabetes Mellitus". The authors conclude that
- Achieved significant reductions in HbA1c (up to 1.4%).
- Achieved significant reductions in weight (up to 2.0 kg)
- Was extremely well tolerated with minimal rates of drug-related
nausea, vomiting and diarrhea that decreased over time.
- Showed low immunogenicity and reproducible pharmacokinetics with a
half-life of approximately one week.
- Is a highly soluble liquid formulation that is injectable in a small
volume (less than or equal to 0.2 mL) with a 31 gauge needle.
Injection site adverse events were rare and actually less frequent in
the treatment groups than the placebo groups.
- The excellent GI tolerability allows the possibility of dose-
optimization with higher doses.
The second poster is entitled: "PC-Insulin, a New Basal Insulin with
Longer Duration of Activity". The authors conclude that PC-Insulin:
- Retained the ability to activate the human insulin receptor but did
not display undesirable mitogenicity.
- Was more effective than insulin Glargine following single and daily
multi-dose injections in diabetic rats.
- Displayed extended pharmacokinetic profiles in various preclinical
- Is a promising candidate for the next generation of long-lasting
ConjuChem, a developer of next generation medicines from therapeutic
peptides, creates long-acting compounds based on its proprietary
bioconjugation platform technology. The Company has two major development
programs: PC-DAC(TM):Exendin-4, a GLP-1 receptor agonist in Phase II clinical
development and PC-Insulin, a long-acting basal insulin in preclinical
Detailed descriptions of the Company and its technologies can be viewed
on the Company's website www.conjuchem.com.
Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause ConjuChem's actual results, performance or achievements
to be materially different from those expressed or implied by any of the
Company's statements. Actual events or results may differ materially. We
disclaim any intention, and assume no obligation, to update these
For further information:
For further information: Mark Perrin, President and CEO, ConjuChem
Biotechnologies Inc., (514) 844-5558 ext 311, email@example.com; James
Smith, Investor Relations, (416) 815-0700 ext. 229, JSmith@equicomgroup.com